In a report released today, Matthew O’Brien from Piper Sandler maintained a Hold rating on Avita Medical (RCEL – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $8.35.
O’Brien covers the Healthcare sector, focusing on stocks such as Penumbra, Alphatec Holdings, and Boston Scientific. According to TipRanks, O’Brien has an average return of 6.1% and a 51.74% success rate on recommended stocks.
Avita Medical has an analyst consensus of Moderate Buy, with a price target consensus of $23.20.
RCEL market cap is currently $215.4M and has a P/E ratio of -5.97.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCEL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avita Medical (RCEL) Company Description:
Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.
